BioVie Investors Alert: Bragar Eagel & Squire Investigating Potential Claims

Bragar Eagel & Squire is investigating potential claims against BioVie Inc. on behalf of long-term stockholders following a class action complaint filed against the company on January 19, 2024. The complaint alleges that BioVie's board of directors breached their fiduciary duties. Shareholders who suffered losses between August 5, 2021, and November 29, 2023, are encouraged to contact Brandon Walker or Marion Passmore directly to discuss their options.

BioVie Inc. (NASDAQ: BIVI) is facing potential legal action from long-term stockholders following a class action complaint filed against the company on January 19, 2024. The complaint alleges that the company's board of directors breached their fiduciary duties. Stockholders who suffered losses between August 5, 2021, and November 29, 2023, are encouraged to contact Brandon Walker or Marion Passmore directly to discuss their options BioVie Inc. - Special Call^[1].

The lawsuit comes at a time when BioVie has been making significant strides in its clinical trials and drug development efforts. The company recently reported that enrollment in its Parkinson's Phase II clinical trial has picked up, with full enrollment expected by the end of 2025, and top-line data expected in April 2026 . Additionally, the company's long COVID Phase II trial is enrolling well, and its ascites Phase III clinical trial protocol has been submitted to the FDA .

BioVie's lead drug candidate, bezisterim, has shown promising results in clinical trials, demonstrating the ability to reduce inflammation and improve muscle control in Parkinson's patients . The company's second drug candidate, BIV201, is being developed as a potential therapeutic for ascites, a condition with a high mortality rate .

Despite these advancements, the potential legal action could pose a distraction for BioVie and impact its stock price. The company's cash runway is sufficient to cover its expenses until the end of 2026, which is beyond the expected timelines for its Parkinson's and long COVID trials .

For investors and financial professionals, it is crucial to stay informed about the developments in this case and assess the potential impact on BioVie's financial health and stock performance. As the legal process unfolds, it will be essential to monitor the company's progress in its clinical trials and drug development efforts.